Cargando…
Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
BACKGROUND: Synucleinopathies of the aging population are an heterogeneous group of neurological disorders that includes Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) and are characterized by the progressive accumulation of α-synuclein in neuronal and glial cells. Toll-like receptor 2...
Autores principales: | Kim, Changyoun, Spencer, Brian, Rockenstein, Edward, Yamakado, Hodaka, Mante, Michael, Adame, Anthony, Fields, Jerel Adam, Masliah, Deborah, Iba, Michiyo, Lee, He-Jin, Rissman, Robert A., Lee, Seung-Jae, Masliah, Eliezer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085656/ https://www.ncbi.nlm.nih.gov/pubmed/30092810 http://dx.doi.org/10.1186/s13024-018-0276-2 |
Ejemplares similares
-
Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells
por: Kim, Changyoun, et al.
Publicado: (2021) -
Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies
por: Kwon, Somin, et al.
Publicado: (2019) -
Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
por: Iba, Michiyo, et al.
Publicado: (2020) -
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
por: Spencer, Brian, et al.
Publicado: (2017) -
Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
por: Valera, Elvira, et al.
Publicado: (2017)